From rheumatoid arthritis to HIV, the pharmaceutical industry is well on its way to making this a banner year for new drug implementation. Here are just a few exciting breakthroughs for big pharma in 2020.
Hulio Injection for Arthritis and Other Diseases
Mylan Pharmaceuticals Inc. has proven they are a company that can get significant results. On July 6, the FDA approved Mylan’s Hulio Injection, a tumor necrosis factor (TNF) blocker that reduces the symptoms of inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and plaque psoriasis.
Rukobia Extended-Release Tablets for HIV
For some patients who have HIV, there are few treatment options, that is, until now. Those who are resistant to other drugs, Rukobia (fostemsavir) is a first-in-class attachment inhibitor for the treatment of HIV-1 infection. Approved on July 2, 2020, Rukobia is used in combination with other antiretrovirals (ARV) for patients who are resistant to a wide range of therapies, or where safety is a consideration.
Phesgo Injection for Breast Cancer
Unfortunately, even with the best surgical procedures and advanced interventions, some forms of breast cancer have a high likelihood of returning, which is where Phesgo comes in.
It was approved in June 2020 for use in conjunction with other drugs to fight the early stages of breast cancer. It is also used in combination with docetaxel for metastatic breast cancer patients who have not received chemotherapy.